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AbsTrACT
Objective to evaluate time trends in the use of 
catheter and surgical procedures, and associated survival 
in isolated congenital shunt lesions.
Methods nationwide, retrospective observational 
study of the UK national congenital heart Disease 
audit database from 2000 to 2016. Patients undergoing 
surgical or catheter procedures for atrial septal defect 
(including sinus venosus defect), patent foramen 
ovale, ventricular septal defect and patent arterial duct 
were included. temporal changes in the frequency of 
procedures, and survival at 30 days and 1 year were 
determined.
results 40 911 procedures were performed, 16 604 
surgical operations and 24 307 catheter-based 
interventions. transcatheter procedures increased 
over time, overtaking surgical repair in 2003–2004, 
while the number of operations remained stable. 
trends in interventions differed according to defect 
type and patient age. catheter closure of atrial septal 
defects is now more common in children and adults, 
although surgical interventions have also increased. 
Patent foramen ovale closure in adults peaked in 
2009–2010 before falling significantly since. surgery 
remains the mainstay for ventricular septal defect in 
infants and children. Duct ligation is most common in 
neonates and infants, while transcatheter intervention is 
predominant in older children. excluding duct ligation, 
survival following surgery was 99.4% and ≈98.7%, 
and following catheter interventions was 99.7% and 
≈99.2%, at 30 days and 1 year, respectively.
Conclusions trends in catheter and surgical techniques 
for isolated congenital shunt lesions plot the evolution 
of the specialty over the last 16 years, reflecting 
changes in clinical guidelines, technology, expertise and 
reimbursement, with distinct patterns according to lesion 
and patient age.
InTrOduCTIOn
Surgical repair has been the mainstay of treatment 
for structural congenital heart defects in children 
and adults for over half a century. However, over 
the last 20 years, interventional catheter procedures 
have emerged as an alternative to surgery for some 
lesions, with the potential for anatomical correc-
tion but reduced early morbidity.1 With advances 
in technology, increased availability and refine-
ment of indications, catheter interventions have 
become the procedure of choice in many centres 
for the treatment of isolated shunt lesions: atrial 
septal defect (ASD), patent foramen ovale (PFO), 
ventricular septal defect (VSD) and patent arterial 
duct (PDA). The relative use of surgical or catheter 
procedures for different lesions, age groups and 
centres is unknown.
The National Congenital Heart Disease Audit 
(NCHDA) is a national database that collects vali-
dated electronic data on all cardiac surgical and 
therapeutic cardiac catheterisation procedures from 
specialist centres in the UK and Ireland.2 Their 
website contains a public record of the number of 
procedures reported since 2000, by year, proce-
dure, age group and centre. We therefore used 
NCHDA data to analyse trends in surgical and 
catheter procedures for the management of isolated 
shunt lesions.
MeThOds
Surgical and catheter procedures for the treatment 
of isolated shunt lesions from 1 April 2000 to 31 
March 2016 were identified from the NCHDA 
database.2 As an audit of publicly available anony-
mised summary data, National Health Service 
(NHS) ethical approval was not required. Data were 
collected by procedural code, financial year, age 
group and centre in March 2018. Catheter codes for 
‘ASD closure (catheter)’, ‘PFO closure (catheter)’, 
‘VSD closure (catheter)’ and ‘PDA closure (cath-
eter)’ were used. Surgical codes for ‘ASD repair’, 
‘Sinus venosus ASD and/or PAPVC repair’, ‘VSD 
repair’, ‘Multiple VSD closure’ and ‘PDA ligation 
(surgical)’ were collected; codes for more complex 
procedures such as ‘Atrioventricular septal defect 
(partial) repair’ were not included. Patient age was 
defined according to standard reported categories: 
neonate (0–30 days), infant (31 days–1 year), child 
(1–16 years) and adult (>16 years). Survival at 30 
days and 1 year were recorded; these are calculated 
from the dates of intervention and death, with 
mortality tracking from the Office for National 
Statistics (ONS). Missing cases were combined 
with known survivors to calculate ‘assumed alive’ 
as an upper limit of survival probability at 1 year. 
The number of live births and total UK population 
each year over the same period were obtained from 
ONS.3 4
statistical methods
Statistical analysis was performed using Excel 
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(https://www. r- project. org/). Categorical data were expressed as 
counts and percentages. Fisher’s exact test was used to compare 
categorical variables and trends in interventions were assessed 
using Kendall’s method.
resulTs
A total of 40 911 procedures for isolated shunt lesions in the 
UK and Ireland were recorded between 2000 and 2016, 
16 604 surgical operations and 24 307 catheter-based inter-
ventions. Paediatric procedures were performed at 16 centres, 
adult surgery at 33 centres and adult catheter interventions at 
34 centres, including procedures in patients aged >16 years 
performed at ‘paediatric’ centres. The number of sites reporting 
data to NCHDA by year is shown in the online supplementary 
eFigure A.
The number of catheter procedures per year has increased 
(τ=0.63, p<0.001), overtaking surgical repair in 2003–2004 
and peaking at 2056 interventions in 2010–2011 (figure 1); 
the subsequent fall is consistent with the reduction in adult 
PFO device closures (figure 3). Surgical procedures also rose 
during the study period (τ=0.5, p<0.001), but have plateaued 
at around 1000 operations per year. The rate of live births 
increased by an average of 0.9% per year and total UK popu-
lation grew by 0.7% per year over the same period. Summary 
tables for each defect by intervention, age group and year are 
available in the online supplementary eTable 1–7 .
Overall survival following surgical repair was 99.1% at 30 days 
and up to 97.8% at 1 year; after excluding PDA ligation, which 
accounted for 80% of postoperative deaths, survival for ASD/
VSD repair was 99.4% and up to 98.7% at 30 days and 1 year, 
respectively. Following catheter interventions, overall survival 
was 99.7% at 30 days and up to 99.2% at 1 year, although 
outcome was significantly worse after VSD device closure than 
surgical repair (95.7% vs 99.4% at 30 days, p<0.001) and 
following PDA ligation than device occlusion (95.6% vs 99.8%, 
p<0.001). A breakdown for each lesion is shown in table 1 and 
by year quartile is shown in the online supplementary  etable 8 .
Atrial septal defect
ASD device closures more than doubled from 323 in 2000–2001 
to 708 in 2015–2016, primarily due to a rise in procedures 
performed in adults during the first half of the series, increasing 
from 110 in 2000–2001 to 432 in 2008–2009 (figure 2). There 
was not a corresponding fall in surgical ASD closures, which 
remained between 370 and 430 per year in recent years. While 
most surgical ASD closures are performed during childhood, 
catheter interventions have increased in this cohort, such that 
device closure is now the more common intervention. The rise 
in adult catheter device closures over the first 6 years occurred at 
established congenital heart disease centres (τ=1, p=0.008) with 
no significant increase over the last decade (τ=0.36, p=0.18), as 
shown in the online supplementary eFigure B.
Comparing the ratio of catheter with surgical ASD interven-
tions, there was a rise in the proportion of device closures from 
2000–2001 to 2006–2007 (τ=0.52, p=0.006) reaching a plateau 
over the last decade (see online supplementary eFigure C). Of 
note, the number of reported surgical closures of sinus venosus 
defects increased significantly from 29 (5.4% of ASDs, 11.6% 
Figure 1 Trends in the total number of surgical and catheter 
procedures performed for isolated shunt lesions.
Table 1 Number of cases and survival at 30 days and 1 year following intervention, by defect and intervention
defect Intervention Cases
30-day survival 1-year survival
Alive dead unknown Known alive dead unknown Assumed alive*
ASD, no. (%) Catheter 9263 9245 (99.8) 14 (0.2) 4 (0.04) 9263 (86.3) 64 (0.7) 1205 (13.0) 9199 (99.3)
Surgery 5755 5727 (99.5) 26 (0.45) 2 (0.03) 4733 (82.2) 49 (0.9) 973 (16.9) 5706 (99.1)
PFO, no. (%) Catheter 6465 6451 (99.8) 14 (0.2) 0 6118 (94.6) 39 (0.6) 308 (4.8) 6426 (99.4)
VSD, no. (%) Catheter 604 578 (95.7) 25 (4.1) 1 (0.17) 489 (81.0) 33 (5.5) 82 (13.6) 571 (94.5)
Surgery 5623 5588 (99.4) 33 (0.6) 2 (0.04) 4390 (78.1) 102 (1.8) 1131 (20.1) 5521 (98.2)
PDA, no. (%) Catheter 7975 7962 (99.8) 13 (0.2) 0 6533 (81.9) 48 (0.6) 1394 (17.5) 7927 (99.4)
Surgery 5226 4997 (95.6) 228 (4.4) 1 (0.02) 3874 (74.1) 576 (11.0) 776 (14.8) 4650 (89.0)
Overall, no. (%) Catheter or surgery 40 911 40 548 (99.1) 353 (0.9) 10 (0.02) 34 131 (83.4) 911 (2.2) 5869 (14.3) 40 000 (97.8)
*Assumed alive=known alive+unknown.
ASD, atrial septal defect; PDA, patent arterial duct; PFO, patent foramen ovale; VSD, ventricular septal defect.
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of ASD surgery) in 2001–2002 to 129 (11.3% of ASDs, 31.3% 
of ASD surgery) in 2013–2014 (τ=0.8, p<0.001) (see online 
supplementary eFigure D).
Patent foramen ovale
PFO device closures are almost exclusively performed in adults 
(98.9%). There was a marked rise in the number of procedures 
performed, from 1 case in 2000–2001 to a peak of 899 cases in 
2009–2010, followed by a fall to around 450 per year in recent 
years (figure 3).
Ventricular septal defect
Surgical VSD repair is performed more commonly than catheter 
device closure, with the latter accounting for only 9.7% of VSD 
interventions. Most VSDs are closed surgically during infancy 
with around a quarter closed after 1 year of age but very few in 
adulthood (figure 4). Catheter procedures are most commonly 
performed in children with a peak at 42 cases/year in 2004–
2005, with most of these procedures performed at three centres 
(Birmingham, Bristol, Royal Brompton). Adults are the only 
group in whom device closure is more common than surgery but 
the absolute numbers of interventions are low.
Patent arterial duct
Most PDA interventions are performed by catheter in children 
over 1 year of age (figure 5) in whom isolated surgical ligation 
is rare. The number of device occlusions in infants has also 
increased (τ=0.62, p=0.001). Surgical PDA ligations in neonates 
have reduced by 58.2% in the last 5 years, from a peak of 177 
cases in 2010–2011 to 74 cases in 2015–2016, with a similar fall 
(273–183, 33.0%) in infants. PDA intervention is uncommon in 
adults.
dIsCussIOn
In this study of the UK national database for congenital heart 
disease interventions, we analysed trends in surgical and catheter 
procedures for the management of isolated shunt lesions since 
2000. We found a significant rise in catheter interventions but 
without any discernible impact on the number of patients under-
going surgical repair, in the context of only low-level growth 
in the UK population. The evolution of management strategies 
varied according to lesion type and patient age; compare the 
growth of catheter interventions for ASD in adults with the 
minimal impact on the management of isolated VSD in infants 
and young children. Overall survival was excellent (>99%) at 
30 days for all lesions other than VSD device closure (95.7%) 
and PDA ligation (95.6%), but all patient groups had ongoing 
attrition between 30 days and 1 year.
Few other studies have compared multicentre experiences of 
catheter and surgical procedures in the management of non-com-
plex lesions in children and adults. In a Danish national study, 
Larsen et al found similar practice for the period 2003–2015, 
with catheter procedures commonly used for ASD (48.2%) or 
PDA (72.2%) but rarely in VSD (2.4%)5; they reported 100% 
30-day and 98%–100% 1-year survival following intervention 
in these conditions. The IMproving Pediatric and Adult Congen-
ital Treatment (IMPACT) registry collects data on catheter inter-
ventions from 81 US centres and reported that in 2011–2013, 
73.0% of ASD device closures were performed in children 
(1–18 years) and 25.5% in adults6; this differs from our finding 
of 36.2% in children and 63.5% in adults for the same period 
and likely reflects a selection bias towards paediatric centres in 
their registry. In contrast, their report of 26.1% of PDA occlu-
sions in infants and 70.0% in children is similar to our find-
ings of 20.9% and 72.7%, respectively. The IMPACT registry 
does not collect data on surgical interventions and therefore 
cannot provide relative trends in resource utilisation over time. 
Conversely, Brown et al used NCHDA data to assess trends in 
30-day mortality for all paediatric cardiac surgery in the UK 
and found that mortality in the lowest risk cases fell from 1.4% 
Figure 3 Trends in closure of patent foramen ovale in adults by 
catheter device.
Figure 4 Trends in closure of ventricular septal defects by surgical 
repair or catheter device.
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(95% CI 0.6 to 2.1) in 2000–2001 to 0.5% (95% CI 0.2 to 0.7) 
in 2009–2010 (p<0.01)7; outcomes of catheter interventions 
were not assessed.
The increase in catheter interventions over recent years has 
been driven by advances in non-invasive diagnostic imaging, 
catheter design and device technology. These have led to widened 
indications for catheter intervention and the expansion of paedi-
atric and adult congenital interventional cardiology exper-
tise.8–10 In contrast, there has been minimal change in operative 
technique or the availability of surgical services. The impact of 
these contrasting patterns on clinical practice has varied by the 
type of congenital heart defect.
Atrial septal defect
ASD device closure has doubled over the last 16 years, with a 
near fourfold increase in adults (figure 2) and is now the stan-
dard of care for anatomically suitable lesions8 10; most of this rise 
reflects a genuine change in practice at established adult congen-
ital heart centres rather than reporting of catheter procedures at 
additional sites, as shown in the online supplementary eFigure 
B. Despite this, the number of surgical ASD closures in adults 
has also increased, perhaps due to concerns over late device 
erosion in high-risk groups.11 In patients with a haemodynam-
ically significant shunt but without pulmonary hypertension, 
closure is associated with better outcomes, fewer atrial arrhyth-
mias, improved functional capacity and long-term survival.12 13 
This is considered a class I (symptomatic) or class IIa (asymptom-
atic) indication in the recent adult American Heart Association 
(AHA)/American College of Cardiology guidelines,9 and a class I 
indication regardless of symptoms in the current paediatric AHA 
and adult European Society of Cardiology guidelines.8 10 The 
best outcome is achieved in patients undergoing closure before 
25 years of age,14 while intervention after 40 years does not 
affect the frequency of atrial arrhythmias.15
Secundum ASDs account for 80% of cases and most are 
amenable to percutaneous device closure8 10; surgical repair 
is indicated primarily when the rim of septal tissue is <5 mm 
and therefore inadequate for device placement.9 10 On the 
other hand, sinus venosus defects (5%–10%) are usually only 
amenable to surgical closure due to the associated partial anoma-
lous pulmonary venous drainage of the right lung. The apparent 
rise in sinus venosus closure is likely to reflect more accurate 
diagnosis of right heart volume loading on echocardiography 
and classification in reported data rather than a true increase in 
the incidence or rate of surgical intervention (see online supple-
mentary eFigure D).
Patent foramen ovale
The rapid rise in off-label PFO device closures between 2003 
and 2010 was driven by the belief that it may have widespread 
therapeutic benefit in conditions such as migraine headache and 
cryptogenic stroke.16 However, three randomised controlled 
trials in recurrent migraine, including the controversial Migraine 
Intervention with STARFlex Technology (MIST) trial in the UK 
published in 2008,17 showed no benefit for migraine preven-
tion18; routine PFO closure was not recommended by the UK 
National Institute for Health and Care Excellence guideline in 
2010,19 coinciding with a sharp decline in procedures (figure 3). 
Similarly, in recurrent stroke, several trials failed to demon-
strate clinical benefit or cost-effectiveness,20 leading to the with-
drawal of NHS repayment in 2016. Current AHA/American 
Stroke Association guidelines do not support PFO closure in 
patients with cryptogenic stroke without evidence of a deep vein 
thrombosis (class III),21 although recent trial evidence suggests 
the superiority of device closure over medical therapy.22 It there-
fore is likely that device closure of PFO for the prevention of 
recurrent cryptogenic stroke will be performed more frequently.
Ventricular septal defect
Surgical closure remains the standard of care for patients 
with an isolated haemodynamically significant VSD.8–10 
Most perimembranous defects require closure in early child-
hood which may be complicated by complete atrioventric-
ular block, requiring permanent pacemaker insertion early 
after surgery in 1.1% of cases.23 Despite advances in cath-
eter technology, clinical concerns remain regarding device 
migration and delayed heart block, which may occur late 
after implantation in up to 5% of perimembranous VSDs and 
therefore present a risk of sudden death in the community.24 
A recent meta-analysis of transcatheter device closure for 
perimembranous VSD in 54 studies found a pooled estimates 
of heart block at 1.1%, residual shunt at 15.9%, arrhyth-
mias at 10.3% and valvular defects at 4.1%25; yet it was 
limited by the inclusion of 53 cohort studies but only one 
early phase clinical trial. The rate of complications is highest 
in smaller children who comprise most patients undergoing 
closure, which may explain the lack of uptake (figure 4).26 
Device closure is considered as an alternative to surgery in 
paediatric and adult patients with a muscular VSD with an 
adequate rim of septal myocardium,8 9 as well as in those 
with a residual shunt after surgical repair. The higher 30-day 
mortality observed for device closure (4.1%) compared 
with surgery (0.6%) may reflect selection of high-risk cases 
considered less attractive for surgical closure or cumulative 
learning curves across centres.
Patent arterial duct
The choice of technique for preventing flow in a persistent PDA 
is primarily determined by patient age/size. Transcatheter occlu-
sion is performed mostly during childhood, although its use 
in infants increased during the study without a corresponding 
fall in surgery, suggesting a more proactive approach. In chil-
dren, occlusion is indicated for a moderate or large PDA with 
a haemodynamically significant left-to-right shunt (class I), 
and reasonable for a small left-to-right shunt that is audible on 
auscultation (class IIa).8
Surgical ligation via a lateral thoracotomy remains the proce-
dure of choice in neonates, who are usually premature with very 
low birth weight, failure to thrive and remain ventilator-depen-
dent. Thirty-day (4.4%) and 1-year (11.0%) mortality remain 
high, reflecting their poor physiological state and comorbidities. 
However, we found the number of neonates and infants under-
going surgical ligation fell by 58.2% and 33.0%, respectively 
over the last 5 years (figure 5), suggesting a move away from 
referral for intervention and appears consistent across centres 
(see online supplementary eFigure E). Bixler et al reported a 
similar trend in US neonatal intensive care units with a 53% 
decrease in PDA ligation over the last decade, with a fall across 
83% of units.27 This move towards conservative management 
reflects the growing belief that PDA closure does not improve 
neonatal outcomes.28
Transcatheter PDA occlusion is rarely performed in preterm 
neonates as the manufacturer currently recommends the duct 
occluder in patients >6 kg. A recent UK study demonstrated 
its feasibility and efficacy in infants <6 kg (mean 4.9±1.0 kg), 
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follow-up (2.6±2.4 years) with 10% incidence of moderate-
to-major adverse events and no procedure-related deaths.29 
Moreover, echocardiographic-guided duct occlusion in 
extremely premature infants (mean 1.25 kg) has been shown 
to be achievable with minimal procedural morbidity.30 No 
published data directly compares outcomes of surgical liga-
tion and transcatheter occlusion in preterm infants.28
limitations
All congenital heart units in the UK and Ireland routinely submit 
data to NCHDA but other cardiac centres (NHS and private) 
either joined during the study period or do not participate 
(see online supplementary eFigure A). This may underestimate 
the number of cases, particularly adult ASD and PFO closures 
performed at non-adult congenital heart disease (ACHD) centres; 
data on patients over 16 years therefore are likely incomplete. 
Reorganisation of services over the last two decades may also 
have affected capture as centres opened, closed or merged and 
may have contributed to overall trends.
As data are categorised by procedural code rather than diag-
nosis, heterogeneity within categories cannot be determined 
and patients with more complex treatment pathways may 
have been included, for example, catheter closure of a residual 
VSD postsurgery in a more complex condition, retrieval of an 
embolised device with surgical closure, and combined or staged 
procedures for multiple VSDs using combined approaches. 
Similarly, the use of broad age categories does not allow accu-
rate determination of age at procedure and therefore whether 
there are trends towards earlier or later interventions. The 
focus on isolated shunt lesions excluded other conditions 
in which the rise in catheter interventions has impacted on 
surgery, such as balloon dilatation, stenting and transcatheter 
valve implantation.
Finally, data on survival are near-complete at 30 days but 
there is a significant proportion of missing data at 1 year 
(table 1). As NCHDA routinely perform mortality tracking 
via ONS for deaths registered in the UK, missing cases are 
likely but not proven to be alive. Excluding missing cases 
would lead to a significant underestimation of survival and 
therefore the sums of ‘known alive’ and ‘unknown’ are 
included as ‘assumed alive’.
COnClusIOns
Trends in catheter and surgical techniques for the treatment 
of isolated congenital shunt lesions plot the evolution of the 
specialty over the last 16 years. They reflect changes in clin-
ical guidelines, technology, expertise and reimbursement, and 
have distinct patterns according to lesion type and patient age. 
Catheter device closure has become the procedure of choice 
for ASD, especially in adults but the marked increase in proce-
dures has not reduced surgical workload. On the other hand, 
it has had minimal impact on the management of VSD during 
childhood; this may change with improving device technology 
and techniques, and accumulating evidence of better safety and 
efficacy. PFO closure underwent a period of rapid growth with 
widespread clinical adoption before evidence from several clin-
ical trials failed to show benefit and it was not recommended 
in national guidelines, leading to a sharp decline. Finally, there 
has been little change in the management of PDA, although the 
coming years will determine the extent of the rise of catheter 
occlusion in small children and decline of surgical ligation in 
premature infants. 
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Key messages
What is already known on this subject?
 ► Surgical repair has been the mainstay of treatment for 
congenital heart disease in children and adults.
 ► With advances in technology and availability, transcatheter 
procedures are commonly used in many centres for isolated 
shunt defects with reduced early morbidity.
What might this study add?
 ► In this study of 40 911 children and adults undergoing 
intervention from 2000 to 2016, the use of catheter and 
surgical techniques varied according to lesion type and 
patient age.
 ► Catheter intervention has become the procedure of choice for 
atrial septal defect and patent foramen ovale, but there has 
been little change in the management of ventricular septal 
defect or patent arterial duct.
 ► Overall survival was excellent (>99%) at 30 days for all 
lesions other than ventricular septal defect device closure 
(95.7%) and patent arterial duct ligation (95.6%), but all 
patient groups had ongoing attrition between 30 days and 
1 year.
how might this impact on clinical practice?
 ► Transcatheter interventions for isolated shunt lesions have 
increased over recent years but with little impact on surgical 
workload.
 ► With advances in technology and expansion of indications, it 
is likely that catheter interventions will continue to increase 
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